Clovis Oncology Inc. [NASDAQ: CLVS] traded at a low on 05/06/22, posting a -32.56 loss after which it closed the day’ session at $0.99. The company report on May 5, 2022 that Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference.
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time. The conference will be held at the Encore hotel in Las Vegas.
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
The results of the trading session contributed to over 36690773 shares changing hands. Over the past one week, the price volatility of Clovis Oncology Inc. stands at 19.75% while the volatility over the past one month is 12.38%.
The market cap for CLVS stock reached $211.58 million, with 129.98 million shares outstanding and 128.04 million shares in the current float. Compared to the average trading volume of 11.52M shares, CLVS reached a trading volume of 36690773 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Clovis Oncology Inc. [CLVS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $2.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $29 to $33. The new note on the price target was released on May 18, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $5, while SVB Leerink analysts kept a Underperform rating on CLVS stock.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.32, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 1.46.
How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -50.43. With this latest performance, CLVS shares dropped by -64.47% in over the last four-week period, additionally sinking by -78.31% over the last 6 months – not to mention a drop of -82.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 25.91, with the RSI for the last a single of trading hit 17.64, and the three-weeks RSI is set at 31.72 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 1.9518, while it was recorded at 1.6543 for the last single week of trading, and 3.2139 for the last 200 days.
Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.60.
Insider trade positions for Clovis Oncology Inc. [CLVS]
There are presently around $66 million, or 37.40% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: STATE STREET CORP with ownership of 16,114,542, which is approximately 9.811% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 10,115,101 shares of the stock with an approximate value of $10.02 million in CLVS stocks shares; and BLACKROCK INC., currently with $9.64 million in CLVS stock with ownership of nearly 2.501% of the company’s market capitalization.
Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 83 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 9,734,981 shares. Additionally, 58 investors decreased positions by around 4,980,717 shares, while 41 investors held positions by with 51,734,065 shares. The mentioned changes placed institutional holdings at 66,449,763 shares, according to the latest SEC report filing. CLVS stock had 28 new institutional investments in for a total of 2,200,344 shares, while 21 institutional investors sold positions of 687,817 shares during the same period.